Model Informed Drug Development Will Face Adoption Friction Yet Ultimately Support A Steady Outlook

AnalystLowTarget

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

06 Jan 26

Updated

16 Jul 26

Views

Not Invested

Shared on 16 Jul 26

Fair value Decreased 33%

CERT: Growth Reset And Lower P E Multiple Will Pressure Returns

Certara’s outlook takes a hit as expectations for its growth cool and more analysts cut what they think the business is worth. The update also flags uncertainty around how quickly new leadership can turn investment spending into steadier results, even as profitability holds up and new AI partnerships and offerings roll out.

3 views

Fair Value vs Share Price

US$6

vs US$8.1535.8% overvalued

0.08%

Revenue growth

6.7%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Certara

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with moderate growth potential.

Market capUS$1.2b

PB1.3x

Estimated Growth1.5%

Dividend YieldN/A

Full analysis

CEO & management

Jon Resnick

CEO

1.1yrs

CEO Tenure

Provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.